Neurology: Examining the Effects of Comorbidities on Disease-Modifying Therapy Use in Multiple Sclerosis is organized by American Academy of Neurology (AAN) and will be held during Apr 05, 2016 - Apr 05, 2019.
The target audience for this medical event is physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine. This CME Conference has been approved for a maximum of 0.75 AMA PRA Category 1 Credits.
Learning Objectives :
Upon completion of the article by Zhang et al, the participant should be able to:
• State approximately what percentage of patients in this study had at least one comorbidity
• Discuss which factors were associated with an increased or decreased likelihood of disease modifying therapy (DMT) initiation
• Discuss which specific comorbidities were associated with an increased or decreased likelihood of DMT initiation
Additional details will be posted as soon as they are available.